Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01313572 · ClinicalTrials.gov registry record · Phase 3
Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI
A Phase 3 study, sponsored by Forest Laboratories.
- Terminated
- Registry status
- Phase 3
- Development phase
- 197
- Enrollment target
NCT01313572: Clinical Trial Phase 3 study, sponsored by Forest Laboratories.
NCT01313572 is a Phase 3 study that was terminated before completion, run by Forest Laboratories. The registered enrollment target is 197 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01313572, a Phase 3 study, was terminated before completion, sponsored by Forest Laboratories.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 197 participants
- Enrollment target
Study Summary
The purpose of this study is to see whether apadenoson is as effective as adenosine when used as a pharmacological stress agent in myocardial SPECT-imaging (SPECT-MPI)to detect defects in the supply of blood to the heart muscle (myocardial perfusion defects). The study will also look at whether apadenoson is better tolerated than adenosine when used in SPECT-MPI.
Interventions
- DRUG Apadenoson SPECT-MPI
- DRUG Adenosine SPECT-MPI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 197 participants |
| Start Date | 2011-08 |
| Est. Completion | 2012-04 |
| Phase | Phase 3 |
Why NCT01313572 stopped before completion
NCT01313572 is an interventional study that assigns participants to a tested intervention. The registered 197 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 2 interventions - of which Apadenoson SPECT-MPI is the first listed.
NCT01313572 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01313572 about?
NCT01313572 is a clinical study titled "Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI". The purpose of this study is to see whether apadenoson is as effective as adenosine when used as a pharmacological stress agent in myocardial SPECT-imaging (SPECT-MPI)to detect defects in the supply of blood to the heart muscle (myocardial perfusion defects). The study will also look at whether apad...
What is the current status of trial NCT01313572?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 197 participants. The study started on 2011-08. Estimated completion is 2012-04.
What interventions are being tested in trial NCT01313572?
The interventions under investigation include: Apadenoson SPECT-MPI (DRUG), Adenosine SPECT-MPI (DRUG).
Who is sponsoring clinical trial NCT01313572?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01313572's enrollment target sits among peer trials
197 1390th of 2000 higher than 611 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04219254 · 197 participants · Phase 1
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
- NCT06173778 · 197 participants · Phase 2
Semaglutide for Post-Smoking Cessation Weight Management
- NCT05203328 · 198 participants · NA
Prospective Study to Evaluate High Flow Nasal Cannula With Monitored Anesthesia Care During EBUS Bronchoscopy
- NCT05426967 · 198 participants · NA
rTMS for Military TBI-related Depression
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia